stoxline Quote Chart Rank Option Currency Glossary
Atreca, Inc. (BCEL)
0.241  -0.022 (-8.3%)    12-08 16:00
Open: 0.2699
High: 0.2699
Volume: 1,071,654
Pre. Close: 0.2628
Low: 0.235
Market Cap: 10(M)
Technical analysis
2023-12-08 4:41:51 PM
Short term     
Mid term     
Targets 6-month :  0.31 1-year :  0.37
Resists First :  0.27 Second :  0.31
Pivot price 0.22
Supports First :  0.18 Second :  0.15
MAs MA(5) :  0.23 MA(20) :  0.22
MA(100) :  0.39 MA(250) :  0.87
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  41.1 D(3) :  43.4
RSI RSI(14): 51.2
52-week High :  2.04 Low :  0.18
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ BCEL ] has closed below upper band by 20.3%. Bollinger Bands are 76.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 20 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.27 - 0.27 0.27 - 0.27
Low: 0.23 - 0.23 0.23 - 0.23
Close: 0.24 - 0.24 0.24 - 0.24
Company Description

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.

Headline News

Tue, 14 Nov 2023
Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of ... - Yahoo Finance

Thu, 19 Oct 2023
Why Netflix Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Atreca (NASDAQ - Benzinga

Thu, 12 Oct 2023
Mid-Peninsula project rode biotech's boom. Now it's showing how to survive the bust - San Francisco Business Times - The Business Journals

Tue, 10 Oct 2023
Why Immunic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Atreca (NASDAQ - Benzinga

Thu, 21 Sep 2023
Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross - GlobeNewswire

Mon, 14 Aug 2023
Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37% - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 33 (M)
Shares Float 27 (M)
Held by Insiders 4.1 (%)
Held by Institutions 44.4 (%)
Shares Short 2,990 (K)
Shares Short P.Month 2,930 (K)
Stock Financials
EPS -2.5
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.27
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -51.3 %
Return on Equity (ttm) -182.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.33
Qtrly Earnings Growth 0 %
Operating Cash Flow -65 (M)
Levered Free Cash Flow -26 (M)
Stock Valuations
PE Ratio -0.1
PEG Ratio 0
Price to Book value 0.89
Price to Sales 0
Price to Cash Flow -0.13
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android